Ms Sarah Meibush

Sarah Meibusch was brought up on a Qld beef cattle property and is passionate about the Australian agriculture and food industry. She is a motivated, high achieving life science leader.  Currently a Principal at one of Australia’s largest venture capital firms, OneVentures, she is responsible for sourcing life sciences companies and actively shaping their future. She applies her global executional experience and entrepreneurial passion to nurture their success. Her enterprise level leadership experience has been forged over 20 years in a wide spectrum of organisations, including start-up, private companies, ASX and NASDAQ-listed companies, multi-national companies and university research organisations.

Prior to OneVentures, she was the Asian Business Development lead for Shire Pharmaceuticals (now Takeda), a global specialty pharmaceutical company. Sarah identified technologies and developed collaborations across Japan, Korea, Australia, New Zealand, Singapore and Taiwan including playing a key role in sourcing the $300M Fibrotech deal announced in 2015. Sarah has a strong operational understanding life science industries gained through senior management roles at the Progen Pharmaceuticals, The University of Queensland’s QAAFI institute, Beef CRC and Pyxis Genomics.

Sarah is a graduate of the Australian Institute of Company Directors (GAICD) and currently holds directorships with Kira Biotech, Axial Therapeutics and Life Sciences Queensland and serves as an alternate director and observer with Vaxxas, Clinical Genomics and Blade Therapeutics. She is an advisory board member to the Ausbiotech Investment Committee and Early Stage Investment Forum. She holds Bachelor level agricultural science qualifications from the University of Queensland and a Masters from Cornell University and has completed a postgraduate course at Harvard Business School focusing on negotiation and decision making.